|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:ATCCode
|
gptkb:L01XE29
|
|
gptkbp:CASNumber
|
417716-92-8
|
|
gptkbp:chemicalFormula
|
C21H19ClN4O4
|
|
gptkbp:combinationTherapy
|
gptkb:pembrolizumab
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:drugClass
|
antineoplastic agent
|
|
gptkbp:form
|
gptkb:tablet
capsule
|
|
gptkbp:genericName
|
gptkb:lenvatinib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lenvima
|
|
gptkbp:indication
|
gptkb:cancer
hepatocellular carcinoma
renal cell carcinoma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Eisai
|
|
gptkbp:mechanismOfAction
|
gptkb:receptor_tyrosine_kinase
|
|
gptkbp:patentExpired
|
2028 (US, estimated)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
fatigue
hypertension
weight loss
proteinuria
arthralgia
decreased appetite
|
|
gptkbp:target
|
gptkb:FGFR3
gptkb:FGFR1
gptkb:KIT
gptkb:VEGFR1
gptkb:VEGFR2
gptkb:RET
gptkb:FGFR4
gptkb:FGFR2
gptkb:PDGFRα
gptkb:VEGFR3
|
|
gptkbp:bfsParent
|
gptkb:Merck_&_Co.
|
|
gptkbp:bfsLayer
|
4
|